List of Canasa drug patents

Canasa is owned by Allergan.

Canasa contains Mesalamine.

Canasa has a total of 2 drug patents out of which 0 drug patents have expired.

Canasa was authorised for market use on 05 January, 2001.

Canasa is available in suppository;rectal dosage forms.

The generics of Canasa are possible to be released after 06 June, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8436051 ALLERGAN Mesalamine suppository
Jun, 2028

(5 years from now)

US8217083 ALLERGAN Mesalamine suppository
Jun, 2028

(5 years from now)

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 05 January, 2001

Treatment: NA

Dosage: SUPPOSITORY;RECTAL

How can I launch a generic of CANASA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic